Native MS of Daptomycin in Nanodiscs
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive UHMR
ORGANISM(S): Bacteria
SUBMITTER: 
Michael Marty
PROVIDER: MSV000090729 | MassIVE | Wed Nov 16 15:21:00 GMT 2022
REPOSITORIES: MassIVE
Similar Datasets
Project description:Native MS data examining incorporation of daptomycin into intact nanodiscs at different concentrations and with different lipids
2022-11-16 | MSV000090729 | GNPS
Project description:FPOP data examining solvent exposure of daptomycin at different concentrations in the presence of nanodiscs with different lipids
2022-11-01 | MSV000090629 | MassIVE
Project description:Native MS data of alanine-scanning mutants. Includes raw data at different source temperatures, with different mutants, three replicates, and with different lipids added. Early data was collected with separate raw files for each temperature. Later files were collected with a temperature ramp, so all temperatures are collected as different time steps inside a single raw file.
2024-10-21 | MSV000096149 | MassIVE
Project description:Glomus sp. MS strain:MS Genome sequencing
| PRJNA210520 | ENA
Project description:Methanosarcina barkeri MS strain:MS Raw sequence reads
| PRJNA613292 | ENA
Project description:we develop a robut low input cell and high throughput single cell ChIP method used for both native and fixed in vitro cultured cells and intact tissue
2019-07-15 | GSE129328 | GEO
Project description:Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course.
| PRJEB28543 | ENA
Project description:We report the transcriptomic analyses of a tropical coralliomrpharian, Ricordea yuma, following the establishment of symbiosis with either native symbiont or non-native symbiont. We examined the expression profiles, and results showed distinct metabolic consequences for the cnidarian host when they host different symbionts.
2019-02-27 | GSE125433 | GEO
Project description:Only 59% of Alaska Native people have been adequately screened for colorectal cancer (CRC) despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. The long-term study goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations responsible for providing health care to geographically remote Alaska Native communities. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health setting or among rural/remote populations. Using the Social Ecological Model, the research will be multi-level, examining influence on patients, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MT-sDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are not adherent to CRC screening guidelines and interviews with healthcare providers will be used to identify factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide evidence on the MT-sDNA usefulness (MT-sDNA sample quality and neoplastic yield) as well as the first data on MT-sDNA follow up adherence rates in the Alaska Native population, which will inform plans to scale-up the intervention model. This research has the potential to sustainably improve public health by increasing CRC screening rates among a rural/remote tribal population as well as provide a model for other integrated health systems that provide care to high-risk or underserved populations in the U.S. and worldwide.
| 2335242 | ecrin-mdr-crc
Project description:Lipids comprise 70% of the myelin sheath, and autoantibodies against lipids may contribute to the demyelination that characterizes multiple sclerosis (MS). We used lipid antigen microarrays and lipid mass spectrometry to identify bona fide lipid targets of the autoimmune response in MS brain and an animal model of MS to explore the role of the identified lipids in autoimmune demyelination. We found that autoantibodies in MS target a phosphate group in phosphatidylserine and oxidized phosphatidylcholine derivatives. Administration of these lipids ameliorated experimental autoimmune encephalomyelitis by suppressing activation and inducing apoptosis of autoreactive T cells, effects mediated by the lipids' saturated fatty-acid side chains. Thus, phospholipids represent a natural anti-inflammatory class of compounds that have potential as novel therapeutics for MS. Fig. 1A. Lipid-array profiling of IgG+IgM antibody reactivity in cerebrospinal fluid (CSF) samples from MS patients (relapsing remitting MS; secondary progressive MS; primary progressive MS), healthy controls, and other neurological disease controls. Lipid hits with the lowest FDR (q=0.048) were clustered according to their reactivity profiles. 48 different lipids were custom-spotted in duplicate using the CAMAG Automatic TLC Sampler (ATS4) robot to spray 200 nl of 10 to 100 pmol of lipids onto PVDF membranes affixed to the surface of microscope slides. The slides were probed with cerebrospinal fluid (CSF) from 59 human patient samples. 60 slides total: 18 relapsing-remitting MS, 14 secondary-progressive MS, 1 primary-progressive MS, 21 other neurological disease, 5 healthy control, 1 secondary Ab alone (not included in this submission). CSF diluted 1/10. HRP-conjugated secondary Ab (goat anti-human IgM/IgG) diluted 1/8000. ECL for 3 minutes.
2012-05-08 | E-GEOD-37664 | biostudies-arrayexpress